Recent advances regarding the role of ABC subfamily C member 10(ABCC10) in the efflux of antitumor drugs

作     者：Rishil J.Kathawala Yi-Jun Wang Charles R.Ashby Jr Zhe-Sheng Chen 

作者机构：Department of Pharmaceutical SciencesCollege of Pharmacy and Health SciencesSt.John’s University 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2014年第33卷第5期

页      面：223-230页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by funds from the National Institute of Health (No.1R15CA143701) St.John's University Research Seed Grant (No.579-1110-7002) to Z.S.Chen 

主　　题：抗肿瘤药物 家族 酪氨酸激酶抑制剂 外排 多药耐药 磷酸二酯酶 转运体 埃坡霉素 

摘      要：ABCC10,also known as multidrug-resistant protein 7(MRP7),is the tenth member of the C subfamily of the ATP-binding cassette(ABC) ***10 mediates multidrug resistance(MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor *** ABCC10 transporter is a 171-kDa protein that is localized on the basolateral cell ***10 is a broad-specificity transporter of xenobiotics,including antitumor drugs,such as taxanes,epothilone B,vinca alkaloids,and cytarabine,as well as modulators of the estrogen pathway,such as *** recent years,ABCC10 inhibitors,including cepharanthine,lapatinib,erlotinib,nilotinib,imatinib,sildenafil,and vardenafil,have been reported to overcome ABCC10-mediated *** review discusses some recent and clinically relevant aspects of the ABCC10 drug efflux transporter from the perspective of current chemotherapy,particularly its inhibition by tyrosine kinase inhibitors and phosphodiesterase type 5 inhibitors.